Jun 2026 (Q2 FY26) — Jul 29, 2026
Pulmonx Q2 FY26 — Re-accelerating Sales Growth and Operating Leverage
Read the full callPulmonx (LUNG) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Pulmonx earnings: last reported Wed, 29 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 22.8 | −4.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -39.8 | +22.3 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -10.1 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.75 −1.69% · −$0.03
Performance +15.1% 1Y
1Y: $1.52 on 17 Oct 2025 → $1.75. High $2.6 (19 Dec 2025), low $1.17 (27 Mar 2026).
- Previous close
- $1.78
- 52-week range
- $1.17 – $2.6
- One year
- +4.79%
Overview
- Symbol
- LUNG
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Pulmonx earnings calls (LUNG)
Financials
What the filings say
Net profit, year on year: +34% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 20 | 24 | 23 | 24 | 22 | 23 | 21 | 23 |
| Operating profit | -14 | -13 | -15 | -15 | -14 | -10 | -13 | -9 |
| Operating margin | −69.3% | −56.5% | −64.6% | −62.0% | −66.9% | −43.8% | −62.9% | −39.8% |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | -14 | -13 | -14 | -15 | -14 | -10 | -14 | -10 |
| Tax rate | −1.4% | −0.3% | −0.9% | −1.2% | −0.9% | −1.8% | −1.1% | −1.3% |
| Net profit | -14 | -13 | -14 | -15 | -14 | -10 | -14 | -10 |
| EPS ($ per share) | -0.36 | — | -0.36 | -0.38 | -0.34 | — | -0.33 | -0.24 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | — | -211 | -243 | -291 | -350 | -411 | -468 | -522 |
| Total liabilities | — | 36 | 38 | 42 | 40 | 59 | 77 | 75 |
| Fixed assets | — | 1 | 1 | 5 | 5 | 4 | 3 | 2 |
| Total assets | — | 54 | 264 | 235 | 194 | 178 | 163 | 129 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -18 | -21 | -31 | -41 | -45 | -38 | -32 | -32 |
| Cash from investing | 0 | -14 | 13 | -46 | -4 | -2 | 17 | 30 |
| Cash from financing | 12 | 46 | 235 | 4 | 2 | 21 | 1 | 1 |
| Net cash flow | -6 | 11 | 217 | -83 | -47 | -18 | -13 | -1 |
| Capital expenditure | -0 | -1 | -1 | -4 | -1 | -1 | -1 | -0 |
| Free cash flow | -19 | -21 | -32 | -45 | -46 | -38 | -33 | -33 |
Insider filings
66 filings between Dec 1, 2025 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$547.9K
55 sales by 5 insiders
2% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 11
- Award — granted as compensation
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| French Glendon E. III | — | $292.3K | Sep 1, 2026 |
| Lehman David Aaron | — | $88.5K | Sep 1, 2026 |
| Radhakrishnan Srikanth | — | $69.5K | Sep 1, 2026 |
| Rose Geoffrey Beran | — | $51.1K | Sep 1, 2026 |
| Florin Daniel P | — | $46.4K | Dec 8, 2025 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Rose Geoffrey Beran Chief Commercial Officer | Sale | 1,530 | $3.5K |
| Sep 1, 2026 | Radhakrishnan Srikanth Chief Science & Techn. Officer | Sale | 2,643 | $6.0K |
| Sep 1, 2026 | Radhakrishnan Srikanth Chief Science & Techn. Officer | Sale | 2,121 | $4.8K |
| Sep 1, 2026 | French Glendon E. III President and CEO | Sale | 4,098 | $9.3K |
| Sep 1, 2026 | French Glendon E. III President and CEO | Sale | 37,784 | $85.4K |
| Sep 1, 2026 | Lehman David Aaron General Counsel | Sale | 4,827 | $10.9K |
| Sep 1, 2026 | Lehman David Aaron General Counsel | Sale | 3,807 | $8.6K |
| Sep 1, 2026 | Lehman David Aaron General Counsel | Sale | 3,476 | $7.9K |
| Sep 1, 2026 | Rose Geoffrey Beran Chief Commercial Officer | Sale | 1,746 | $3.9K |
| Sep 1, 2026 | Lehman David Aaron General Counsel | Sale | 2,224 | $5.0K |
| Sep 1, 2026 | Rose Geoffrey Beran Chief Commercial Officer | Sale | 2,213 | $5.0K |
| Sep 1, 2026 | Radhakrishnan Srikanth Chief Science & Techn. Officer | Sale | 5,863 | $13.3K |
| Sep 1, 2026 | Radhakrishnan Srikanth Chief Science & Techn. Officer | Sale | 3,618 | $8.2K |
| Sep 1, 2026 | Rose Geoffrey Beran Chief Commercial Officer | Sale | 2,390 | $5.4K |
| Jun 5, 2026 | Florin Daniel P Director | Award | 40,000 | $0 |
| Jun 5, 2026 | Ferrari Richard Director | Award | 40,000 | $0 |
| Jun 5, 2026 | Sullivan Tiffany Director | Award | 40,000 | $0 |
| Jun 5, 2026 | Melenikiotou Georgia Director | Award | 40,000 | $0 |
| Jun 5, 2026 | Mead Dana G Jr. Director | Award | 40,000 | $0 |
| Jun 5, 2026 | Burns Thomas William Director | Award | 40,000 | $0 |
| Jun 2, 2026 | French Glendon E. III President and CEO | Sale | 13,511 | $21.2K |
| Jun 1, 2026 | French Glendon E. III President and CEO | Sale | 4,171 | $6.4K |
| Jun 1, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 1,557 | $2.4K |
| Jun 1, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 1,778 | $2.7K |
| Jun 1, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 4,915 | $7.6K |
| Jun 1, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 2,264 | $3.5K |
| Jun 1, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 2,254 | $3.5K |
| Jun 1, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 3,539 | $5.5K |
| Jun 1, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 5,969 | $9.2K |
| Jun 1, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 3,684 | $5.7K |
| Jun 1, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 2,434 | $3.7K |
| Jun 1, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 2,153 | $3.3K |
| Jun 1, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 2,691 | $4.1K |
| Jun 1, 2026 | French Glendon E. III President and CEO | Sale | 38,467 | $59.2K |
| Jun 1, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 3,876 | $6.0K |
| Mar 2, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Award | 100,000 | $0 |
| Mar 2, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 2,911 | $4.2K |
| Mar 2, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 1,861 | $2.7K |
| Mar 2, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 2,125 | $3.0K |
| Mar 2, 2026 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER | Sale | 835 | $1.2K |
| Mar 2, 2026 | Lehman David Aaron GENERAL COUNSEL | Award | 150,000 | $0 |
| Mar 2, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 4,433 | $6.3K |
| Mar 2, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 2,590 | $3.7K |
| Mar 2, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 1,163 | $1.7K |
| Mar 2, 2026 | Lehman David Aaron GENERAL COUNSEL | Sale | 4,051 | $5.8K |
| Mar 2, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Award | 175,000 | $0 |
| Mar 2, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 4,198 | $6.0K |
| Mar 2, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 2,461 | $3.5K |
| Mar 2, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 3,068 | $4.4K |
| Mar 2, 2026 | Radhakrishnan Srikanth Chief Science &Techn. Officer | Sale | 756 | $1.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Pulmonx Corp
Free account. Everything above stays public.
Write why you follow Pulmonx Corp and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading